Gene and virotherapy for hematological malignancies

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Recent years have seen a transformation in the treatment of hematological malignancies. Advances in gene therapy and molecular techniques and significant gains in computational abilities have supported the rapid development of safer and better tolerated therapies for many patients with hematologic cancers. In this review, we discuss novel applications of gene therapy, including immunomodulation and gene silencing, and report on the rise of oncolytic viruses for use in the treatment of malignancies arising in cells of the blood, lymph, and marrow. We discuss the relationship of the tropism of wildtype viruses and their oncolytic behavior as well as the tumoricidal and immunostimulatory properties of a number of attenuated and recombinant viruses currently in clinical development in countries around the world. While we have focused on promising virotherapy applications for future development, we also present a historical perspective and identify areas of potential clinical and regulatory practice change. We outline several of the virus systems being developed for applications in hematology, and summarize efficacy data in the context of ongoing or future human clinical testing. We also present the advantages and limitations of gene and virus therapy, including challenges and opportunities for improved treatment tolerability and outcomes for patients with hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)29-41
Number of pages13
JournalInternational Journal of Hematology
Volume104
Issue number1
DOIs
StatePublished - Jul 1 2016

Bibliographical note

Publisher Copyright:
© 2016, The Japanese Society of Hematology.

Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.

Keywords

  • Clinical trials
  • Gene therapy
  • Immunovirotherapy
  • Purging
  • Virotherapy

Fingerprint Dive into the research topics of 'Gene and virotherapy for hematological malignancies'. Together they form a unique fingerprint.

Cite this